Abstract
Nintedanib Reduces Disease Progression in Patients With Idiopathic Pulmonary Fibrosis Irrespective of Composite Physiologic Index at Baseline in the INPULSIS Trials
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have